{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T23:09:48Z","timestamp":1793660988876,"version":"4.5.1"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,4,24]],"date-time":"2019-04-24T00:00:00Z","timestamp":1556064000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13045-019-0733-6","type":"journal-article","created":{"date-parts":[[2019,4,24]],"date-time":"2019-04-24T12:03:39Z","timestamp":1556107419000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":136,"title":["Ataxia telangiectasia and Rad3-related inhibitors and cancer therapy: where we stand"],"prefix":"10.1186","volume":"12","author":[{"given":"Lin","family":"Mei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junran","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingsong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,4,24]]},"reference":[{"issue":"56","key":"733_CR1","doi-asserted-by":"publisher","first-page":"7749","DOI":"10.1038\/sj.onc.1210880","volume":"26","author":"MF Lavin","year":"2007","unstructured":"Lavin MF. ATM and the Mre11 complex combine to recognize and signal DNA double-strand breaks. Oncogene. 2007;26(56):7749\u201358.","journal-title":"Oncogene."},{"issue":"3","key":"733_CR2","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.radonc.2017.09.043","volume":"126","author":"Z Qiu","year":"2018","unstructured":"Qiu Z, Oleinick NL, Zhang J. ATR\/CHK1 inhibitors and cancer therapy. Radiotherapy Oncol. 2018;126(3):450\u201364.","journal-title":"Radiotherapy Oncol"},{"issue":"1","key":"733_CR3","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/ncb2897","volume":"16","author":"MK Zeman","year":"2014","unstructured":"Zeman MK, Cimprich KA. Causes and consequences of replication stress. Nat Cell Biol. 2014;16(1):2\u20139.","journal-title":"Nat Cell Biol"},{"issue":"5625","key":"733_CR4","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1126\/science.1083430","volume":"300","author":"L Zou","year":"2003","unstructured":"Zou L, Elledge SJ. Sensing DNA damage through ATRIP recognition of RPA-ssDNA complexes. Science (New York, NY). 2003;300(5625):1542\u20138.","journal-title":"Science (New York, NY)"},{"issue":"6","key":"733_CR5","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1007\/PL00008656","volume":"262","author":"Y Liu","year":"2000","unstructured":"Liu Y, Vidanes G, Lin YC, Mori S, Siede W. Characterization of a Saccharomyces cerevisiae homologue of Schizosaccharomyces pombe Chk1 involved in DNA-damage-induced M-phase arrest. Mol Gen Genet. 2000;262(6):1132\u201346.","journal-title":"Mol Gen Genet"},{"issue":"11","key":"733_CR6","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1038\/sj.onc.1207394","volume":"23","author":"L Busino","year":"2004","unstructured":"Busino L, Chiesa M, Draetta GF, Donzelli M. Cdc25A phosphatase: combinatorial phosphorylation, ubiquitylation and proteolysis. Oncogene. 2004;23(11):2050\u20136.","journal-title":"Oncogene."},{"issue":"28","key":"733_CR7","doi-asserted-by":"publisher","first-page":"3977","DOI":"10.1038\/onc.2008.17","volume":"27","author":"EM Bahassi","year":"2008","unstructured":"Bahassi EM, Ovesen JL, Riesenberg AL, Bernstein WZ, Hasty PE, Stambrook PJ. The checkpoint kinases Chk1 and Chk2 regulate the functional associations between hBRCA2 and Rad51 in response to DNA damage. Oncogene. 2008;27(28):3977\u201385.","journal-title":"Oncogene."},{"issue":"2","key":"733_CR8","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1158\/1078-0432.CCR-09-1029","volume":"16","author":"Y Dai","year":"2010","unstructured":"Dai Y, Grant S. New insights into checkpoint kinase 1 in the DNA damage response signaling network. Clin Cancer Res. 2010;16(2):376\u201383.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"733_CR9","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.molmed.2010.10.009","volume":"17","author":"CX Ma","year":"2011","unstructured":"Ma CX, Janetka JW, Piwnica-Worms H. Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics. Trends Mol Med. 2011;17(2):88\u201396.","journal-title":"Trends Mol Med"},{"key":"733_CR10","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/B978-0-12-380888-2.00003-0","volume":"108","author":"J Smith","year":"2010","unstructured":"Smith J, Tho LM, Xu N, Gillespie DA. The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer. Adv Cancer Res. 2010;108:73\u2013112.","journal-title":"Adv Cancer Res"},{"issue":"10","key":"733_CR11","doi-asserted-by":"publisher","first-page":"3805","DOI":"10.1073\/pnas.0611584104","volume":"104","author":"K Zaugg","year":"2007","unstructured":"Zaugg K, Su YW, Reilly PT, Moolani Y, Cheung CC, Hakem R, et al. Cross-talk between Chk1 and Chk2 in double-mutant thymocytes. Proc Natl Acad Sci U S A. 2007;104(10):3805\u201310.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"733_CR12","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1093\/jmcb\/mju045","volume":"6","author":"L Zannini","year":"2014","unstructured":"Zannini L, Delia D, Buscemi G. CHK2 kinase in the DNA damage response and beyond. J Mol Cell Biol. 2014;6(6):442\u201357.","journal-title":"J Mol Cell Biol"},{"issue":"42","key":"733_CR13","doi-asserted-by":"publisher","first-page":"44289","DOI":"10.18632\/oncotarget.6247","volume":"6","author":"FP Vendetti","year":"2015","unstructured":"Vendetti FP, Lau A, Schamus S, Conrads TP, O'Connor MJ, Bakkenist CJ. The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo. Oncotarget. 2015;6(42):44289\u2013305.","journal-title":"Oncotarget."},{"issue":"13 Supplement","key":"733_CR14","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1158\/1538-7445.AM2017-836","volume":"77","author":"AM Wengner","year":"2017","unstructured":"Wengner AM, Siemeister G, Luecking U, Lefranc J, Lienau P, Deeg G, et al. Abstract 836: ATR inhibitor BAY 1895344 shows potent anti-tumor efficacy in monotherapy and strong combination potential with the targeted alpha therapy Radium-223 dichloride in preclinical tumor models. Cancer Res. 2017;77(13 Supplement):836.","journal-title":"Cancer Res"},{"issue":"7","key":"733_CR15","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1038\/nchembio.573","volume":"7","author":"PM Reaper","year":"2011","unstructured":"Reaper PM, Griffiths MR, Long JM, Charrier JD, Maccormick S, Charlton PA, et al. Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR. Nat Chem Biol. 2011;7(7):428\u201330.","journal-title":"Nat Chem Biol"},{"issue":"22","key":"733_CR16","doi-asserted-by":"publisher","first-page":"3541","DOI":"10.4161\/15384101.2014.960729","volume":"13","author":"Y Cui","year":"2014","unstructured":"Cui Y, Palii SS, Innes CL, Paules RS. Depletion of ATR selectively sensitizes ATM-deficient human mammary epithelial cells to ionizing radiation and DNA-damaging agents. Cell Cycle (Georgetown, Tex). 2014;13(22):3541\u201350.","journal-title":"Cell Cycle (Georgetown, Tex)"},{"issue":"10","key":"733_CR17","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1038\/nrm.2017.67","volume":"18","author":"JC Saldivar","year":"2017","unstructured":"Saldivar JC, Cortez D, Cimprich KA. The essential kinase ATR: ensuring faithful duplication of a challenging genome. Nat Rev Mol Cell Biol. 2017;18(10):622\u201336.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"3","key":"733_CR18","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1002\/pmic.201500172","volume":"16","author":"SA Wagner","year":"2016","unstructured":"Wagner SA, Oehler H, Voigt A, Dalic D, Freiwald A, Serve H, et al. ATR inhibition rewires cellular signaling networks induced by replication stress. Proteomics. 2016;16(3):402\u201316.","journal-title":"Proteomics."},{"issue":"2","key":"733_CR19","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1593\/neo.131980","volume":"16","author":"PC Genik","year":"2014","unstructured":"Genik PC, Bielefeldt-Ohmann H, Liu X, Story MD, Ding L, Bush JM, et al. Strain background determines lymphoma incidence in Atm knockout mice. Neoplasia (New York, NY). 2014;16(2):129\u201336.","journal-title":"Neoplasia (New York, NY)"},{"issue":"4","key":"733_CR20","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1101\/gad.14.4.397","volume":"14","author":"EJ Brown","year":"2000","unstructured":"Brown EJ, Baltimore D. ATR disruption leads to chromosomal fragmentation and early embryonic lethality. Genes Dev. 2000;14(4):397\u2013402.","journal-title":"Genes Dev"},{"issue":"28","key":"733_CR21","doi-asserted-by":"publisher","first-page":"3894","DOI":"10.1038\/sj.onc.1209426","volume":"25","author":"KE Adams","year":"2006","unstructured":"Adams KE, Medhurst AL, Dart DA, Lakin ND. Recruitment of ATR to sites of ionising radiation-induced DNA damage requires ATM and components of the MRN protein complex. Oncogene. 2006;25(28):3894\u2013904.","journal-title":"Oncogene."},{"issue":"1","key":"733_CR22","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/ncb1337","volume":"8","author":"A Jazayeri","year":"2006","unstructured":"Jazayeri A, Falck J, Lukas C, Bartek J, Smith GC, Lukas J, et al. ATM- and cell cycle-dependent regulation of ATR in response to DNA double-strand breaks. Nat Cell Biol. 2006;8(1):37\u201345.","journal-title":"Nat Cell Biol"},{"issue":"2","key":"733_CR23","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1084\/jem.20051923","volume":"203","author":"M Cuadrado","year":"2006","unstructured":"Cuadrado M, Martinez-Pastor B, Murga M, Toledo LI, Gutierrez-Martinez P, Lopez E, et al. ATM regulates ATR chromatin loading in response to DNA double-strand breaks. J Exp Med. 2006;203(2):297\u2013303.","journal-title":"J Exp Med"},{"issue":"24","key":"733_CR24","doi-asserted-by":"publisher","first-page":"5775","DOI":"10.1038\/sj.emboj.7601446","volume":"25","author":"T Stiff","year":"2006","unstructured":"Stiff T, Walker SA, Cerosaletti K, Goodarzi AA, Petermann E, Concannon P, et al. ATR-dependent phosphorylation and activation of ATM in response to UV treatment or replication fork stalling. EMBO J. 2006;25(24):5775\u201382.","journal-title":"EMBO J"},{"issue":"11","key":"733_CR25","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1038\/nm.3369","volume":"19","author":"CJ Lord","year":"2013","unstructured":"Lord CJ, Ashworth A. Mechanisms of resistance to therapies targeting BRCA-mutant cancers. Nat Med. 2013;19(11):1381\u20138.","journal-title":"Nat Med"},{"issue":"7","key":"733_CR26","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1038\/cdd.2008.47","volume":"15","author":"H Vakifahmetoglu","year":"2008","unstructured":"Vakifahmetoglu H, Olsson M, Zhivotovsky B. Death through a tragedy: mitotic catastrophe. Cell Death Differ. 2008;15(7):1153\u201362.","journal-title":"Cell Death Differ"},{"issue":"14","key":"733_CR27","doi-asserted-by":"publisher","first-page":"5674","DOI":"10.18632\/oncotarget.2158","volume":"5","author":"AB Hall","year":"2014","unstructured":"Hall AB, Newsome D, Wang Y, Boucher DM, Eustace B, Gu Y, et al. Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970. Oncotarget. 2014;5(14):5674\u201385.","journal-title":"Oncotarget."},{"issue":"1","key":"733_CR28","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1186\/s13046-018-0964-3","volume":"37","author":"GJ Yoshida","year":"2018","unstructured":"Yoshida GJ. Correction to: Emerging roles of Myc in stem cell biology and novel tumor therapies. J Exp Clin Cancer Res. 2018;37(1):285.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"733_CR29","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.ctrv.2013.03.002","volume":"40","author":"E Fokas","year":"2014","unstructured":"Fokas E, Prevo R, Hammond EM, Brunner TB, McKenna WG, Muschel RJ. Targeting ATR in DNA damage response and cancer therapeutics. Cancer Treat Rev. 2014;40(1):109\u201317.","journal-title":"Cancer Treat Rev"},{"issue":"12 Supplement 2","key":"733_CR30","doi-asserted-by":"publisher","first-page":"PR14","DOI":"10.1158\/1535-7163.TARG-15-PR14","volume":"14","author":"TA Yap","year":"2015","unstructured":"Yap TA, Luken MJM, O'Carrigan B, Roda D, Papadatos-Pastos D, Lorente D, et al. Abstract PR14: phase I trial of first-in-class ataxia telangiectasia-mutated and Rad3-related (ATR) inhibitor VX-970 as monotherapy (mono) or in combination with carboplatin (CP) in advanced cancer patients (pts) with preliminary evidence of target modulation and antitumor activity. Mol Cancer Ther. 2015;14(12 Supplement 2):PR14\u2013PR.","journal-title":"Mol Cancer Ther"},{"issue":"15_suppl","key":"733_CR31","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1200\/JCO.2016.34.15_suppl.2504","volume":"34","author":"B O'Carrigan","year":"2016","unstructured":"O'Carrigan B, Luken MJM, Papadatos-Pastos D, Brown J, Tunariu N, Lopez RP, et al. Phase I trial of a first-in-class ATR inhibitor VX-970 as monotherapy (mono) or in combination (combo) with carboplatin (CP) incorporating pharmacodynamics (PD) studies. J Clin Oncol. 2016;34(15_suppl):2504.","journal-title":"J Clin Oncol"},{"issue":"5","key":"733_CR32","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1182\/blood-2015-05-644872","volume":"127","author":"M Kwok","year":"2016","unstructured":"Kwok M, Davies N, Agathanggelou A, Smith E, Oldreive C, Petermann E, et al. ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells. Blood. 2016;127(5):582\u201395.","journal-title":"Blood."},{"issue":"5","key":"733_CR33","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.neo.2018.03.003","volume":"20","author":"J Jin","year":"2018","unstructured":"Jin J, Fang H, Yang F, Ji W, Guan N, Sun Z, et al. Combined inhibition of ATR and WEE1 as a novel therapeutic strategy in triple-negative breast cancer. Neoplasia (New York, NY). 2018;20(5):478\u201388.","journal-title":"Neoplasia (New York, NY)."},{"key":"733_CR34","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.ctro.2018.06.001","volume":"12","author":"MT Dillon","year":"2018","unstructured":"Dillon MT, Boylan Z, Smith D, Guevara J, Mohammed K, Peckitt C, et al. PATRIOT: a phase I study to assess the tolerability, safety and biological effects of a specific ataxia telangiectasia and Rad3-related (ATR) inhibitor (AZD6738) as a single agent and in combination with palliative radiation therapy in patients with solid tumours. Clin Transl Radiation Oncol. 2018;12:16\u201320.","journal-title":"Clin Transl Radiation Oncol"},{"issue":"1","key":"733_CR35","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1002\/ijc.30373","volume":"140","author":"HJ Kim","year":"2017","unstructured":"Kim HJ, Min A, Im SA, Jang H, Lee KH, Lau A, et al. Anti-tumor activity of the ATR inhibitor AZD6738 in HER2 positive breast cancer cells. Int J Cancer. 2017;140(1):109\u201319.","journal-title":"Int J Cancer"},{"key":"733_CR36","doi-asserted-by":"publisher","unstructured":"Wallez Y, Dunlop CR, Johnson TI, Koh SB, Fornari C, Yates JWT, et al. The ATR inhibitor AZD6738 synergizes with gemcitabine in vitro and in vivo to induce pancreatic ductal adenocarcinoma regression. Mol Cancer Ther. 2018;17(8):1670-82. https:\/\/doi.org\/10.1158\/1535-7163.MCT-18-0010 . Epub 2018 Jun 11.","DOI":"10.1158\/1535-7163.MCT-18-0010"},{"key":"733_CR37","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1016\/S0959-8049(16)32607-7","volume":"69","author":"TA Yap","year":"2016","unstructured":"Yap TA, Krebs MG, Postel-Vinay S, Bang YJ, El-Khoueiry A, Abida W, et al. Phase I modular study of AZD6738, a novel oral, potent and selective ataxia telangiectasia Rad3-related (ATR) inhibitor in combination (combo) with carboplatin, olaparib or durvalumab in patients (pts) with advanced cancers. Eur J Cancer. 2016;69:S2.","journal-title":"Eur J Cancer"},{"issue":"4","key":"733_CR38","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.currproblcancer.2017.05.002","volume":"41","author":"R Sundar","year":"2017","unstructured":"Sundar R, Brown J, Ingles Russo A, Yap TA. Targeting ATR in cancer medicine. Curr Probl Cancer. 2017;41(4):302\u201315.","journal-title":"Curr Probl Cancer"},{"issue":"4 Supplement","key":"733_CR39","first-page":"OT2\u201307--OT2","volume":"78","author":"M Telli","year":"2018","unstructured":"Telli M, Lord S, Dean E, Abramson V, Arkenau H-T, Murias C, et al. Abstract OT2\u201307-07: ATR inhibitor M6620 (formerly VX-970) with cisplatin in metastatic triple-negative breast cancer: preliminary results from a phase 1 dose expansion cohort (NCT02157792). Cancer Research. 2018;78(4 Supplement):OT2\u201307--OT2.","journal-title":"Cancer Research"},{"issue":"15_suppl","key":"733_CR40","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1200\/JCO.2016.34.15_suppl.2513","volume":"34","author":"ER Plummer","year":"2016","unstructured":"Plummer ER, Dean EJ, Evans TRJ, Greystoke A, Herbschleb K, Ranson M, et al. Phase I trial of first-in-class ATR inhibitor VX-970 in combination with gemcitabine (Gem) in advanced solid tumors (NCT02157792). J Clin Oncol. 2016;34(15_suppl):2513.","journal-title":"J Clin Oncol"},{"issue":"16","key":"733_CR41","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1200\/JCO.2017.76.6915","volume":"36","author":"A Thomas","year":"2018","unstructured":"Thomas A, Redon CE, Sciuto L, Padiernos E, Ji J, Lee M-J, et al. Phase I study of ATR inhibitor M6620 in combination with topotecan in patients with advanced solid tumors. J Clin Oncol. 2018;36(16):1594\u2013602.","journal-title":"J Clin Oncol"},{"issue":"7563","key":"733_CR42","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nature14664","volume":"524","author":"J George","year":"2015","unstructured":"George J, Lim JS, Jang SJ, Cun Y, Ozretic L, Kong G, et al. Comprehensive genomic profiles of small cell lung cancer. Nature. 2015;524(7563):47\u201353.","journal-title":"Nature."},{"issue":"4","key":"733_CR43","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1093\/annonc\/mdw005","volume":"27","author":"A Dowlati","year":"2016","unstructured":"Dowlati A, Lipka MB, McColl K, Dabir S, Behtaj M, Kresak A, et al. Clinical correlation of extensive-stage small-cell lung cancer genomics. Ann Oncol. 2016;27(4):642\u20137.","journal-title":"Ann Oncol"},{"issue":"2","key":"733_CR44","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.ccell.2017.01.006","volume":"31","author":"EE Gardner","year":"2017","unstructured":"Gardner EE, Lok BH, Schneeberger VE, Desmeules P, Miles LA, Arnold PK, et al. Chemosensitive relapse in small cell lung cancer proceeds through an EZH2-SLFN11 axis. Cancer Cell. 2017;31(2):286\u201399.","journal-title":"Cancer Cell"},{"issue":"1","key":"733_CR45","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1158\/1535-7163.MCT-16-0239","volume":"16","author":"MT Dillon","year":"2017","unstructured":"Dillon MT, Barker HE, Pedersen M, Hafsi H, Bhide SA, Newbold KL, et al. Radiosensitization by the ATR inhibitor AZD6738 through generation of acentric micronuclei. Mol Cancer Ther. 2017;16(1):25\u201334.","journal-title":"Mol Cancer Ther"},{"key":"733_CR46","doi-asserted-by":"publisher","first-page":"e441","DOI":"10.1038\/cddis.2012.181","volume":"3","author":"E Fokas","year":"2012","unstructured":"Fokas E, Prevo R, Pollard JR, Reaper PM, Charlton PA, Cornelissen B, et al. Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation. Cell Death Dis. 2012;3:e441.","journal-title":"Cell Death Dis"},{"issue":"3","key":"733_CR47","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.jdermsci.2016.09.010","volume":"84","author":"E Biskup","year":"2016","unstructured":"Biskup E, Naym DG, Gniadecki R. Small-molecule inhibitors of ataxia telangiectasia and Rad3 related kinase (ATR) sensitize lymphoma cells to UVA radiation. J Dermatol Sci. 2016;84(3):239\u201347.","journal-title":"J Dermatol Sci"},{"issue":"7","key":"733_CR48","first-page":"1307","volume":"8","author":"LL Sun","year":"2018","unstructured":"Sun LL, Yang RY, Li CW, Chen MK, Shao B, Hsu JM, et al. Inhibition of ATR downregulates PD-L1 and sensitizes tumor cells to T cell-mediated killing. Am J Cancer Res. 2018;8(7):1307\u201316.","journal-title":"Am J Cancer Res"},{"issue":"15_suppl","key":"733_CR49","doi-asserted-by":"publisher","first-page":"TPS3120","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS3120","volume":"36","author":"J Heymach","year":"2018","unstructured":"Heymach J, Thomas M, Besse B, Forde PM, Awad MM, Goss GD, et al. An open-label, multidrug, biomarker-directed, multicentre phase II umbrella study in patients with non-small cell lung cancer, who progressed on an anti-PD-1\/PD-L1 containing therapy (HUDSON). J Clin Oncol. 2018;36(15_suppl):TPS3120\u2013TPS.","journal-title":"J Clin Oncol"},{"issue":"12","key":"733_CR50","doi-asserted-by":"publisher","first-page":"3683","DOI":"10.1158\/0008-5472.CAN-13-0110","volume":"73","author":"CJ Huntoon","year":"2013","unstructured":"Huntoon CJ, Flatten KS, Wahner Hendrickson AE, Huehls AM, Sutor SL, Kaufmann SH, et al. ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status. Cancer Res. 2013;73(12):3683\u201391.","journal-title":"Cancer Res"},{"issue":"26","key":"733_CR51","doi-asserted-by":"publisher","first-page":"3474","DOI":"10.1038\/onc.2014.276","volume":"34","author":"M Krajewska","year":"2015","unstructured":"Krajewska M, Fehrmann RS, Schoonen PM, Labib S, de Vries EG, Franke L, et al. ATR inhibition preferentially targets homologous recombination-deficient tumor cells. Oncogene. 2015;34(26):3474\u201381.","journal-title":"Oncogene."},{"issue":"16","key":"733_CR52","doi-asserted-by":"publisher","first-page":"8311","DOI":"10.1093\/nar\/gky625","volume":"46","author":"D Kim","year":"2018","unstructured":"Kim D, Liu Y, Oberly S, Freire R, Smolka MB. ATR-mediated proteome remodeling is a major determinant of homologous recombination capacity in cancer cells. Nucleic Acids Res. 2018;46(16):8311\u201325.","journal-title":"Nucleic Acids Res"},{"issue":"15_suppl","key":"733_CR53","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.1200\/JCO.2018.36.15_suppl.2549","volume":"36","author":"GHOS Coyne","year":"2018","unstructured":"Coyne GHOS, Do KT, Kummar S, Takebe N, Quinn MF, Piha-Paul SA, et al. Phase I trial of the triplet M6620 (formerly VX970) + veliparib + cisplatin in patients with advanced solid tumors. J Clin Oncol. 2018;36(15_suppl):2549.","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"733_CR54","doi-asserted-by":"publisher","first-page":"TPS1116","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS1116","volume":"36","author":"A Tutt","year":"2018","unstructured":"Tutt A, Stephens C, Frewer P, Pierce A, Rhee J, So K, et al. VIOLETTE: A randomized phase II study to assess DNA damage response inhibitors in combination with olaparib (Ola) vs Ola monotherapy in patients (pts) with metastatic, triple-negative breast cancer (TNBC) stratified by alterations in homologous recombination repair (HRR)-related genes. J Clin Oncol. 2018;36(15_suppl):TPS1116\u2013TPS.","journal-title":"J Clin Oncol"},{"issue":"9","key":"733_CR55","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/s41568-018-0034-3","volume":"18","author":"E Lecona","year":"2018","unstructured":"Lecona E, Fernandez-Capetillo O. Targeting ATR in cancer. Nat Rev Cancer. 2018;18(9):586\u201395.","journal-title":"Nat Rev Cancer"}],"container-title":["Journal of Hematology & Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-019-0733-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13045-019-0733-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-019-0733-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,16]],"date-time":"2022-09-16T19:31:46Z","timestamp":1663356706000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-019-0733-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,24]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["733"],"URL":"https:\/\/doi.org\/10.1186\/s13045-019-0733-6","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,24]]},"assertion":[{"value":"20 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Zhang has received consulting and speaker honorarium from AstraZeneca and consulting honorarium from Bayer.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"43"}}